Alnylam Pharma (ALNY) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LVS
9. LRCX
10. MRK

Go back to Alnylam Pharma (ALNY) Reports In-Line Q3 EPS

Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period

November 9, 2015 7:00 AM EST

Advanced Late-Stage Clinical Pipeline: Patisiran APOLLO Phase 3 Trial on Track to Complete Enrollment in Next 3-4 Months; if Positive, Expect NDA Filing in 2017

Presented Positive Clinical Data for ALN-PCSsc for Hypercholesterolemia and ALN-AS1 for Acute Hepatic Porphyrias

Maintained Strong Balance Sheet with $1.34 Billion in Cash and Expect to End 2015 with Greater than $1.2 Billion in Cash

Hosting R&D Day on December 10, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More